Cat. No. 4175
Chemical Name: N-3-Pyridinyl-4-[[3-[[5-(trifluorom
Biological ActivitySelective fatty acid amide hydrolase (FAAH) inhibitor (Ki = 0.23 μM). Reduces inflammatory pain via a cannabinoid receptor-dependent mechanism. Highly efficacious and selective in vivo. Displays no activity at FAAH-2 (IC50 >10 μM).
Licensing InformationSold for research purposes under agreement from Pfizer Inc.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Safety Data Sheet
Ahn et al (2009) Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain. Chem.Biol. 16 411. PMID: 19389627.
Ahn et al (2009) Fatty acid amide hydrolase as a potential therapeutic target for the treatment of pain and CNS disorders. Expert Opin.Drug Discov. 4 763. PMID: 20544003.
If you know of a relevant citation for this product please let us know.
View Related Products by Target
Keywords: PF 3845, supplier, pfizer, cannabinoid, receptors, fatty, acid, amide, hydrolase, FAAH, inhibitors, PF3845
Find multiple products by catalog number
New Products in this Area
Ces3 and Ces1f inhibitor968
Allosteric inhibitor of glutaminaseARN 272
FAAH-like anandamide transporter (FLAT) inhibitorML 349
Selective and reversible lysophospholipase 2 (LYPLA2) inhibitorJJKK 048
Potent and selective MAGL inhibitorML 348
Selective and reversible lysophospholipase 1 (LYPLA1) inhibitor
September 5 - 8, 2015